Monitor HR during therapy. Bronchospastic disease. Pheochromocytoma. Surgery. Diabetes. May mask signs and increase risk for hypoglycemia. Hyperthyroidism. Avoid abrupt cessation. Hepatic impairment.

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.

A pheochromocytoma tumor ... went through with treatment for the tumor in October and suffered a setback post-surgery, but earlier today, she provided an uplifting update on her X account.

At the Baylor College of Medicine Endocrine Surgery Clinics, Drs ... hyperparathyroidism, adrenal masses, pheochromocytoma, Cushing’s syndrome and Conn’s syndrome. A new procedure allows surgeons, ...

The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.

Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in patients with advanced, unresectable, or metastatic pheochromocytoma and ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA ...

Monitor hepatic function; discontinue at first sign of liver injury. COPD. Pheochromocytoma. Diabetes. Surgery. Avoid abrupt cessation (ischemic heart disease may be exacerbated). Elderly.

Bilateral optic disc swelling is an important clinical sign that can reflect a variety of inflammatory, infectious, toxic, metabolic, genetic, or vascular conditions, such as hypertension. [1] It ...

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

The FDA has accepted Merck's (NYSE:MRK) supplemental New Drug Application with priority review for its drug Welireg, also known as belzutifan, for the treatment of a rare type of adrenal gland tumors.